Curie Therapeutics Raises $75M to Change Cancer Care Forever

Curie Therapeutics, a biotechnology startup based in Boston, has raised $75 million in Series A funding to develop precision radiopharmaceuticals that change how solid tumors are dealt with by medical professionals.

The funding round saw the participation of RA Capital Management, Atlas Venture, and Access Biotechnology, the three firms that incubated Curie Therapeutics. The capital will allow the startup to accelerate the development of its multimodal pipeline of precision radiopharmaceuticals after emerging from an 18-month stealth period. Dr. Kevin Bitterman, Partner at Atlas Ventures and a member of Curie’s BoD, referred to the round by stating:

“All three syndicate members showed an early interest in the radiopharmaceutical space. We have been incubating Curie for 18 months with a focus on building a fully integrated company in which both peptidic and non-peptidic ligand R&D, radiochemistry, CMC and clinical translation can occur under one roof.”

Founded in 2020 with the mission to bring radiobiology and radiochemistry together to develop a novel method for frank tumor ablation with a heavy focus on safety and effectiveness. For this purpose, the startup is taking advantage of radiopharmaceuticals’ ability to selectively identify and deliver radiation to tumors, reducing the negative effects of traditional therapy. Dr. Simon Read, Curie Founder and Chief Executive Officer, said in this regard:

“We envision a world where cancer care is transformed by precision radiopharmaceuticals and a future in which these drugs are increasingly integrated into mainstream treatment.”

A 2017 study showed that more than 86% of chemotherapy patients experienced adverse effects when undergoing treatment, which can affect their willingness to continue the treatment. By developing a new and more effective way to deal with cancer while also reducing the negative side effects, Curie Therapeutics could help millions of patients to deal with one of the most severe diseases known to humankind.